Clarus Therapeutics is a men’s health specialty pharmaceutical company commercializing JATENZO®, a twice daily oral testosterone (T) replacement therapy (TRT) for men with hypogonadism (low testosterone).
After USFDA approval on March 27, 2019, the Company launched JATENZO on February 10, 2020. JATENZO has 3 years of market exclusivity until March 27, 2022 and U.S. patent protection through 2030. The Company believes JATENZO will significantly expand treatment options for men diagnosed with symptomatic T deficiency. Currently, the only approved oral TRT option available in the U. S. is methyl testosterone but it has been associated with serious liver toxicity. In contrast, liver toxicity has not been observed in men treated with JATENZO..